Ethical Challenges at End-of-Life
The capabilities of medicine and technology have evolved to provide ever increasingly complex care and keep patients alive in health states that they might not desire. This has created an added responsibility for the physician to anticipate future care needs and to guide treatments as patients become more ill and less functional. Advance care planning is an essential tool in the physician’s armamentarium and this skill set must be honed to ensure that patients receive care consistent with their informed preferences and appropriate to their prognosis. In this activity, Dr. Wenger will discuss the components of advance care planning including serial discussion with patients about clinical circumstances and prognosis, incorporating specific tools, coordinating among the team of physicians caring for a patient across venues of care. He will address how to building strong relationships with patients and families, and keep a consistent focus on goals of care to provide high quality treatment and achieve optimal end-of-life care.
Pamela Kushner, MD, FAAFP (Reviewer): Speaker’s Bureau for AstraZeneca; and Janssen Pharmaceuticals, Inc. Consultant for AstraZeneca; Boehringer Ingelheim; Janssen Pharmaceuticals, Inc.; and Lilly. Advisory Board for Pfizer, Inc.
Patrick Alguire, MD, FACP (Reviewer): Stock Holder for Amgen Inc; Bristol-Myers Squibb; Express Scripts; GlaxoSmithKline PLC; Medtronic Inc; Stryker Corporation; Teva Pharmaceutical Industries.
All other non-faculty contributors to planning, development, editing and review of content have no financial relationships to disclose.
Pri-Med – UCLA
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.